INVESTER I SANGAMO THERAPEUTICS MED ENDAVU: Køb Sangamo Therapeutics ($GBY) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Sangamo Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company specializing in genomic medicine. Headquartered in Richmond, California, Sangamo focuses on developing gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and genome regulation approaches to address serious and often debilitating diseases. Its platform is built around proprietary zinc finger DNA-binding protein technology, designed to enable precise genome editing and targeted gene regulation. Today, Sangamo’s programs concentrate largely on neurological and other severe genetic conditions for which existing treatments offer limited or primarily symptomatic relief. The company’s work spans research, development, and clinical testing of novel therapeutic candidates intended for use by healthcare providers and biopharmaceutical partners. Operating within the broader healthcare and biotechnology sectors, Sangamo Therapeutics plays a specialized role in advancing next-generation genetic medicines that aim to reshape treatment paradigms for patients with significant unmet medical needs. Founded in 1995 in the United States, it remains focused on translating ground-breaking science into practical therapeutic applications.